Methods and compositions for diagnosis and management of neurodegerative diseases
Described herein are assays, methods, and devices for diagnosing/prognosing Alzheimer's disease (AD) and/or a neurodegenerative disease in a subject. The assays, methods, and/or devices described herein can be configured to detect GAS5 long-coding RNAs and/or expression thereof in a sample from a subject.
1. A method of treating Alzheimer's disease, diabetes, or diabetes and Alzheimer's disease in a subject in need thereof, the method comprising:
administering a therapeutically effective amount of a compound having a structure of formula 1
wherein R 1 is a methyl, an isobutane, a phenyl, an indole, or a butanamine,
wherein R 2 is an ethylbenzene, an ethylcyclohexane, an isopentane, a phenyl, a propanamine, or a methylcyclopropane,
wherein R 3 is a methylcyclopropane, a propionic acid, an ethylbenzene, or a propanamine
wherein R 4 is a butanamine, a propionic acid, or a phenyl,
wherein R 5 is a methylcyclopropane, a propionic acid, or an ethylbenzene,
wherein R 6 is a phenyl, a propionic acid, an isobutene, and
wherein R 7 is a phenyl, a propionic acid, a butanamine, or a methyl;
or a pharmaceutical formulation thereof, to the subject in need thereof.
2. The method of claim 1 , wherein the compound has a structure according to any one of Formulas 3-4, 6-19,
3. The method of claim 2 , wherein the compound is capable of binding a GAS5 long non-coding RNA.
4. The method of claim 3 , wherein the GAS5 long non-coding RNA has a sequence that is 90%-100% identical to SEQ ID NO: 1.
5. The method of claim 2 , wherein administering occurs via oral, rectal, intraocular, inhaled, intranasal, topical, vaginal, parenteral, subcutaneous, intramuscular, intravenous, or intradermal administration.
6. The method of claim 1 , wherein the compound is capable of binding a GAS5 long non-coding RNA.
7. The method of claim 6 , wherein the GAS5 long non-coding RNA has a sequence that is 90%-100% identical to SEQ ID NO: 1.
8. The method of claim 1 , wherein a pharmaceutical formulation is administered to the subject in need thereof and the pharmaceutical formulation further comprises an agent selected from the group consisting of: antisense or RNA interference molecules, chemotherapeutics, antineoplastic agents, hormones, antibiotics, antivirals, immunomodulating agents, antinausea, pain modifying agents, anti-inflammatory agents, antipyretics, antibiotics, antibodies, antibody fragments, and any combination thereof.
9. The method of claim 1 , further comprising contacting a sample from the subject in need thereof or component thereof with a capture molecule, wherein the capture molecule is configured to specifically bind to a biomarker, wherein the biomarker is gas5 (SNHG2); and detecting specific binding of the biomarker to the capture molecule.
10. The method of claim 9 , wherein the step of detecting specific binding of the biomarker to the capture molecule is performed using a method comprising a technique selected from the group consisting of: array polymerase chain reaction (PCR), quantitative PCR (qPCR), real-time PCR, real-time qPCR, reverse-transcription PCR (RT-PCR), real-time RT-PCR, RT-qPCR, real-time RT-qPCR, digital PCR (dPCR), RNA flare, (LATE)-PCR, RNA flow cytometry, nucleotide sequencing, cell-based RNA detection assays, in situ hybridization, northern blot analysis, and any combination thereof.
11. The method of claim 9 , wherein the capture molecule has a sequence that is 95%-100% identical to any one of SEQ ID NOs.: 2-3.
12. The method of claim 1 , wherein the subject is greater than 45 years of age.
13. The method of claim 1 , wherein the subject is less than 45 years of age.
14. The method of claim 1 , wherein the subject has or is suspected of having diabetes.